



STATE OF IOWA

CHESTER J. CULVER, GOVERNOR
PATTY JUDGE, LT. GOVERNOR

DEPARTMENT OF HUMAN SERVICES
CHARLES J. KROGMEIER, DIRECTOR

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting September 2, 2009

**Location: Learning Resource Center
3550 Mills Civic Parkway
West Des Moines, Iowa**

Time: 9:30 a.m. – 1:30 p.m.

Tentative Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the minutes
 2. Iowa Medicaid Enterprise Update(s)
 3. Case Studies
 4. Public Comment (See Conflict of Interest Disclosure Form)
 5. Prior Authorization
 - a) *Uloric*
 - b) Ketorolac
 - c) Muscle Relaxants
 - d) Antihistamines
 - e) Fentanyl; Short Acting Oral Products
 - f) Pregabalin (*Lyrica*)
 - g) Palivizumab (*Synagis*)
 - i. Article – Meissner, H. C., Bocchini, J. A. Jr. Reducing RSV hospitalizations: AAP modifies recommendations for use of palivizumab in high-risk infants, young children. *AAP News*. 2009; 30 (7).
 - ii. Current Palivizumab PA Form
 - iii. CDC Surveillance Data, 2007-2008 and 2008-2009 RSV Seasons
 6. Public Comment (See Conflict of Interest Disclosure Form)
 7. Focus Studies/Provider Education Initiatives
 - a) Tiotropium plus Ipratropium Focus Study – Follow Up
 - b) ACE Inhibitors Combined with Angiotensin Receptor Blockers – Initial Review
- IOWA MEDICAID ENTERPRISE - 100 ARMY POST ROAD - DES MOINES, IA 50315

- c) Ophthalmic Fluroquinolones and Macrolides for Bacterial Conjunctivitis – Initial Review
 - d) Rate of Compliance with Atypical Antipsychotics – Initial Discussion
 - e) Drugs that cause Edema – Initial Discussion
 - f) Tamoxifen Interactions with Select SSRIs – Initial Discussion
8. Miscellaneous
- a) DUR Digest (Draft) 2009 Volume 22, Number 1
 - b) FUL Update
 - c) MedWatch
9. Executive Closed Session
- a) Approval of Minutes
 - b) Atypical Antipsychotic use in Children Under 2 Years of Age
 - c) Member Profiles
10. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pam Smith, R.Ph., at info@iadur.org or (515) 725-1287